NASDAQ:CLRB

Cellectar Biosciences - CLRB News Headlines

$6.25

+0.37 (+6.29%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.77
▼
$6.76
50-Day Range: $3.57
▼
$6.25
52-Week Range: $3.37
▼
$10.90

Volume: 96,190 shs
Average Volume: 21,534 shs
Market Capitalization: $38.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.25

Get Cellectar Biosciences News Delivered to You Automatically

CLRB Media Mentions By Week

CLRB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CLRB
News Sentiment
▼
0.44

0.63
▲
Average
Medical
News Sentiment

CLRB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CLRB Articles
This Week
▼
16

1
▲
CLRB Articles
Average Week

Source

Source	Headline
	StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) americanbankingnews.com - August 12 at 10:54 AM
	Equities Analysts Set Expectations for Cellectar Biosciences, Inc.'s Q3 2022 Earnings (NASDAQ:CLRB) americanbankingnews.com - August 12 at 3:24 AM
	Cellectar Biosciences, Inc. Expected to Earn Q1 2023 Earnings of ($0.60) Per Share (NASDAQ:CLRB) americanbankingnews.com - August 11 at 3:20 AM
	Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com americanbankingnews.com - August 11 at 2:34 AM
	Cellectar Dips on Q2 Figures baystreet.ca - August 5 at 9:45 AM
	Cellectar Reports Financial Results for Second Quarter 2022 finance.yahoo.com - August 5 at 9:45 AM
	Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com americanbankingnews.com - August 3 at 2:30 AM
	Cellectar Biosciences: Cellectar Announces Stock Consolidation finanznachrichten.de - July 22 at 10:36 AM
	Cellectar Announces Stock Consolidation finance.yahoo.com - July 21 at 7:47 PM
	Cellectar Biosciences, Inc. (CLRB) uk.finance.yahoo.com - July 19 at 10:24 PM
	Cellectar Biosciences GAAP EPS of -$0.10 in-line seekingalpha.com - May 12 at 7:09 AM
	Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update finance.yahoo.com - May 10 at 12:04 PM

	Cellectar Biosciences Gets Positive DMC Review for Waldenstrom's Macroglobulinemia Treatment marketwatch.com - April 26 at 1:22 PM
	Cellectar says committee recommends continuing trial of iopofosine in Waldenstrom’s patients seekingalpha.com - April 26 at 1:22 PM
	Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia finance.yahoo.com - April 26 at 8:22 AM
	Cellectar Biosciences Announces Key Commercial Team Appointments finance.yahoo.com - April 12 at 9:44 AM
	CLRB To Report WM Trial Data In 2H, DICE On Watch, URGN Sees 46%-67% Revenue Growth In 2022 markets.businessinsider.com - March 22 at 5:03 AM
	Here's Why Cellectar Biosciences Shares Are Rising msn.com - March 21 at 7:02 PM
	Recap: Cellectar Biosciences Q4 Earnings benzinga.com - March 21 at 9:18 AM
	Cellectar Biosciences GAAP EPS of -$0.43 beats by $0.01 seekingalpha.com - March 21 at 9:18 AM
	Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update finance.yahoo.com - March 21 at 9:18 AM
	Cellectar to Participate at Upcoming Banking Conferences finance.yahoo.com - March 10 at 8:06 PM
	Cellectar Biosciences appoints Chad Kolean as CFO, Jarrod Longcor as COO seekingalpha.com - February 23 at 10:34 AM
	Cellectar Biosciences Announces Executive Leadership Changes finance.yahoo.com - February 23 at 10:34 AM
	Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year? finance.yahoo.com - January 17 at 6:06 PM
	Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference finance.yahoo.com - January 5 at 12:24 PM
	Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference finance.yahoo.com - January 4 at 11:18 AM
	Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition finance.yahoo.com - December 13 at 10:20 AM
	Cellectar Biosciences Says Co's Iopofosine I-131 Exhibits Signals Of Efficacy In Phase 1 Study For Pediatric Brain And Solid Tumors benzinga.com - November 16 at 2:15 PM
	Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors finance.yahoo.com - November 16 at 9:15 AM
	Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO proactiveinvestors.com.au - November 14 at 10:23 PM
	Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update finance.yahoo.com - November 8 at 1:26 PM
	Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer finance.yahoo.com - November 2 at 11:27 AM
	Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies finance.yahoo.com - October 25 at 9:31 AM

	Cellectar Biosciences (NASDAQ:CLRB) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - September 24 at 8:41 AM
	Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer finance.yahoo.com - September 22 at 7:56 PM
	Cellectar: Preliminary Iopofosine Data I-131 Suggests Safety, Tolerability in Head and Neck Cancer marketwatch.com - September 22 at 2:47 PM
	Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer finance.yahoo.com - September 22 at 9:46 AM
	Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit finance.yahoo.com - September 15 at 8:42 PM
	Cellectar Receives $2M NIH Grant For Rare Lymphoma Study finance.yahoo.com - August 18 at 4:02 PM
	Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia finance.yahoo.com - August 18 at 11:01 AM
	Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 finance.yahoo.com - August 16 at 10:44 AM
	Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update finance.yahoo.com - August 9 at 9:28 AM
	Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc. finance.yahoo.com - July 13 at 1:08 PM
	Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs) finance.yahoo.com - July 12 at 1:13 PM
	Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference finance.yahoo.com - July 8 at 12:24 PM
	Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors finance.yahoo.com - June 24 at 1:24 PM
	Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - June 4 at 9:28 AM
	Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - May 20 at 1:32 PM
	Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 finance.yahoo.com - May 14 at 1:38 PM

Get Cellectar Biosciences News Delivered to You Automatically

This page (NASDAQ:CLRB) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms